Abstract
Common genetic variation has been associated with multiple phenotypic features in Autism Spectrum Disorder (ASD). However, our knowledge of shared genetic factor structures contributing to this highly heterogeneous phenotypic spectrum is limited. Here, we developed and implemented a structural equation modelling framework to directly model genomic covariance across core and non-core ASD phenotypes, studying autistic individuals of European descent with a case-only design. We identified three independent genetic factors most strongly linked to language performance, behaviour and developmental motor delay, respectively, studying an autism community sample (N = 5331). The three-factorial structure was largely confirmed in independent ASD-simplex families (N = 1946), although we uncovered, in addition, simplex-specific genetic overlap between behaviour and language phenotypes. Multivariate models across cohorts revealed novel associations, including links between language and early mastering of self-feeding. Thus, the common genetic architecture in ASD is multi-dimensional with overarching genetic factors contributing, in combination with ascertainment-specific patterns, to phenotypic heterogeneity.
Original language | English |
---|---|
Article number | 1770 |
Pages (from-to) | 1-15 |
Number of pages | 15 |
Journal | Nature Communications |
Volume | 15 |
Early online date | 27 Feb 2024 |
DOIs | |
Publication status | Published - 2024 |
Bibliographical note
Publisher Copyright:© The Author(s) 2024.
Funding
The authors are grateful to all of the families in SPARK, the SPARK clinical sites and SPARK staff. We are grateful to all of the families at the participating Simons Simplex Collection (SSC) sites, as well as the principal investigators (A. Beaudet, R. Bernier, J. Constantino, E. Cook, E. Fombonne, D. Geschwind, R. Goin-Kochel, E. Hanson, D. Grice, A. Klin, D. Ledbetter, C. Lord, C. Martin, D. Martin, R. Maxim, J. Miles, O. Ousley, K. Pelphrey, B. Peterson, J. Piggot, C. Saulnier, M. State, W. Stone, J. Sutcliffe, C. Walsh, Z. Warren, E. Wijsman). We appreciate obtaining access to phenotypic and genetic data on SFARI Base. This work was supported by a grant from the Simons Foundation Autism Research Initiative (SFARI ID: 514787, PI B.S.P.) covering the work of L.D.H., M.B. and M.M.J.D., in addition, to support from the Max Planck Society. F.S., E.V., S.E.F. and B.S.P. were fully supported by the Max Planck Society. C.Y.S. was supported by the UK Medical Research Council (MRC) Integrative Epidemiology Unit at the University of Bristol (MC_UU_00011/3). J.B. was supported by the EU-AIMS and AIMS-2-TRIALS programmes which receive support from Innovative Medicines Initiative Joint Undertaking Grant No. 115300 and 777394, the resources of which are composed of financial contributions from the European Union’s FP7 and Horizon2020 Programmes, and from the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies’ in-kind contributions, and AUTISM SPEAKS, Autistica and SFARI; and by the Horizon2020 supported programme CANDY (Grant No. 847818).
Funders | Funder number |
---|---|
EU-AIMS | |
European Union’s FP7 | |
Horizon 2020 Framework Programme | |
European Federation of Pharmaceutical Industries and Associations | 847818 |
Simons Foundation Autism Research Initiative | 514787 |
Medical Research Council | |
University of Bristol | MC_UU_00011/3 |
Max-Planck-Gesellschaft | |
Innovative Medicines Initiative | 115300, 777394 |